Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rentschler Biopharma, VarmX Partner on Coagulation Therapy | Contract Pharma

What are you searching for?

Sign in
Breaking News

Rentschler Biopharma, VarmX Partner on Coagulation Therapy

Rentschler to manufacture VarmX’s VMX-C001 for Phase 3 development and potential commercialization.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma
Rentschler Biopharma

Rentschler Biopharma, a global CDMO for biopharmaceuticals, and VarmX, a biotech company developing direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and treatment of inherited coagulation disorders, entered a collaboration for the manufacture VarmX’s lead program, VMX-C001, for Phase 3 development and potential commercialization.

VMX-C001 is a novel treatment to restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs.

Rentschler Biopharma began supporting early development of VMX-C001 in 2022 at its Laupheim, Germany site and VarmX has since initiated its Phase 3 program using GMP material from Rentschler. All subsequent Phase 3 clinical supply, including process validation, will be manufactured at Rentschler Biopharma’s Milford, MA site as part of the transition into late-stage clinical and commercial production. 

Rentschler has expertise in producing a variety of biologics, including capabilities in intensified, perfusion-based processes, as well as supporting fed-batch strategies.  

VMX-C001 is a modified, human factor X protein, designed to be insensitive to FXa DOACs, effectively bypassing their anticoagulant activity and restoring the coagulation cascade. The product candidate was granted Fast Track Designation by the U.S. FDA and a Phase 1 waiver from Japanese regulator PMDA in September 2025. VarmX signed a global strategic collaboration and option agreement with CSL in September 2025. VarmX plans to initiate its global Phase 3 EquilibriX-S trial in urgent surgery in early 2026.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics